B-cell lymphoma epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(7 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{B-cell lymphoma}}
{{B-cell lymphoma}}
{{CMG}}
{{CMG}} ; {{AE}} {{Adnan Ezici}}
==Overview==
==Overview==
They develop more frequently in older adults and in immunocompromised individuals.
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most of the [[Non-Hodgkin lymphomas]]. The incidence of [[non-Hodgkin lymphoma]] is approximately 18.6 per 100,000 individuals worldwide. The incidence of [[Hodgkin's lymphoma]] is approximately 2-3 per 100,000 individuals in populations of European ancestry. In the year 2018, the mortality rate of [[non-Hodgkin lymphoma]] is approximately 5.1/100,000. In the year 2017, the mortality rate of [[Hodgkin's lymphoma]] is approximately 0.41/100,000.
 
==Epidemiology and Demographics==
==Demographics==
They develop more frequently in older adults and in immunocompromised individuals.


===Incidence===
The incidence of [[non-Hodgkin lymphoma]] is approximately 18.6 per 100,000 individuals worldwide.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> The incidence of [[Hodgkin's lymphoma]] is approximately 2-3 per 100,000 individuals in populations of European ancestry.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref>
===Case-fatality rate/Mortality rate===
In the year 2018, the mortality rate of [[non-Hodgkin lymphoma]] is approximately 5.1/100,000.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref> In the year 2017, the mortality rate of [[Hodgkin's lymphoma]] is approximately 0.41/100,000.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref>
===Age===
[[Non-Hodgkin lymphoma]] (NHL) commonly affects individuals older than 65 years of age. However, some subtypes of NHL (i.e., [[Burkitt lymphoma]]) show a bimodal age distribution. [[Hodgkin's lymphoma]] has a bimodal age distribution with the highest incidence in patients (20-39) years of age and older than 60 years of age.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref>
===Race===
In the US, [[Non-Hodgkin lymphoma]] (NHL) usually affects individuals of the white and non-Hispanic races. Asian/Pacific Islander, American Indian and black individuals are less likely to develop NHL.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. [[Hodgkin's lymphoma]] shows age-specific racial disparities. In patients aged <65 years, individuals of the white race have the highest incidence of Hodgkin's lymphoma. On the other hand, in patients over 65 years old, individuals of Hispanics have the highest incidence of Hodgkin's lymphoma. Regardless of the age, Asian/Pacific Islanders (A/PI) are less likely to develop Hodgkin's lymphoma.<ref name="pmid22241896">{{cite journal |vauthors=Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC |title=Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis |journal=Ann Oncol |volume=23 |issue=8 |pages=2128–2137 |date=August 2012 |pmid=22241896 |doi=10.1093/annonc/mdr578 |url=}}</ref>
===Gender===
Men are more commonly affected by [[Non-Hodgkin lymphoma]] (NHL) than women. The male to female ratio is approximately 2 to 1, however, it's known that the male to female ratio is up to 4 in certain subtypes of NHL<ref name="pmid25386354">{{cite journal |vauthors=Horesh N, Horowitz NA |title=Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy |journal=Rambam Maimonides Med J |volume=5 |issue=4 |pages=e0038 |date=October 2014 |pmid=25386354 |pmc=4222427 |doi=10.5041/RMMJ.10172 |url=}}</ref><ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. Men are more commonly affected by [[Hodgkin's lymphoma]] than women. The male to female ratio is approximately 3 to 2.3, however, it's known that the male to female ratio varies depending on the age. In children aged 15 to 19 year, females are more commonly affected with Hodgkin's lymphoma than males with the M/F ratio of approximately 0.8. <ref name=NCI>{{cite web | title = National Caner Institute Childhood Hodgkin Lymphoma Treatment| url =http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq#cit/section_1.3}}</ref><ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref>
===Region===
The majority of endemic [[Burkitt Lymphoma]], a subtype of NHL, cases are reported in subequatorial Africa.<ref name="pmid33573146">{{cite journal |vauthors=Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P |title=Epidemiology of Non-Hodgkin's Lymphoma |journal=Med Sci (Basel) |volume=9 |issue=1 |pages= |date=January 2021 |pmid=33573146 |pmc=7930980 |doi=10.3390/medsci9010005 |url=}}</ref>. Countries with the highest incidence (age-standardized) of [[Hodgkin's lymphoma]] include Lebanon, Greece, and Montenegro.<ref name="pmid31640759">{{cite journal |vauthors=Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z |title=Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study |journal=J Hematol Oncol |volume=12 |issue=1 |pages=107 |date=October 2019 |pmid=31640759 |pmc=6805485 |doi=10.1186/s13045-019-0799-1 |url=}}</ref>
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
Line 19: Line 29:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Immunology]]

Latest revision as of 09:59, 20 February 2022

B-cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating B-cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

B-cell lymphoma epidemiology and demographics On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of B-cell lymphoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on B-cell lymphoma epidemiology and demographics

CDC on B-cell lymphoma epidemiology and demographics

B-cell lymphoma epidemiology and demographics in the news

Blogs on B-cell lymphoma epidemiology and demographics

Directions to Hospitals Treating B-cell lymphoma

Risk calculators and risk factors for B-cell lymphoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Adnan Ezici, M.D[2]

Overview

B-cell lymphomas include both Hodgkin's lymphomas and most of the Non-Hodgkin lymphomas. The incidence of non-Hodgkin lymphoma is approximately 18.6 per 100,000 individuals worldwide. The incidence of Hodgkin's lymphoma is approximately 2-3 per 100,000 individuals in populations of European ancestry. In the year 2018, the mortality rate of non-Hodgkin lymphoma is approximately 5.1/100,000. In the year 2017, the mortality rate of Hodgkin's lymphoma is approximately 0.41/100,000.

Epidemiology and Demographics

Incidence

The incidence of non-Hodgkin lymphoma is approximately 18.6 per 100,000 individuals worldwide.[1] The incidence of Hodgkin's lymphoma is approximately 2-3 per 100,000 individuals in populations of European ancestry.[2]

Case-fatality rate/Mortality rate

In the year 2018, the mortality rate of non-Hodgkin lymphoma is approximately 5.1/100,000.[1] In the year 2017, the mortality rate of Hodgkin's lymphoma is approximately 0.41/100,000.[3]

Age

Non-Hodgkin lymphoma (NHL) commonly affects individuals older than 65 years of age. However, some subtypes of NHL (i.e., Burkitt lymphoma) show a bimodal age distribution. Hodgkin's lymphoma has a bimodal age distribution with the highest incidence in patients (20-39) years of age and older than 60 years of age.[3]

Race

In the US, Non-Hodgkin lymphoma (NHL) usually affects individuals of the white and non-Hispanic races. Asian/Pacific Islander, American Indian and black individuals are less likely to develop NHL.[1]. Hodgkin's lymphoma shows age-specific racial disparities. In patients aged <65 years, individuals of the white race have the highest incidence of Hodgkin's lymphoma. On the other hand, in patients over 65 years old, individuals of Hispanics have the highest incidence of Hodgkin's lymphoma. Regardless of the age, Asian/Pacific Islanders (A/PI) are less likely to develop Hodgkin's lymphoma.[4]

Gender

Men are more commonly affected by Non-Hodgkin lymphoma (NHL) than women. The male to female ratio is approximately 2 to 1, however, it's known that the male to female ratio is up to 4 in certain subtypes of NHL[5][1]. Men are more commonly affected by Hodgkin's lymphoma than women. The male to female ratio is approximately 3 to 2.3, however, it's known that the male to female ratio varies depending on the age. In children aged 15 to 19 year, females are more commonly affected with Hodgkin's lymphoma than males with the M/F ratio of approximately 0.8. [6][3]

Region

The majority of endemic Burkitt Lymphoma, a subtype of NHL, cases are reported in subequatorial Africa.[1]. Countries with the highest incidence (age-standardized) of Hodgkin's lymphoma include Lebanon, Greece, and Montenegro.[3]

References

  1. 1.0 1.1 1.2 1.3 1.4 Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P (January 2021). "Epidemiology of Non-Hodgkin's Lymphoma". Med Sci (Basel). 9 (1). doi:10.3390/medsci9010005. PMC 7930980 Check |pmc= value (help). PMID 33573146 Check |pmid= value (help).
  2. Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL (July 2020). "Hodgkin lymphoma". Nat Rev Dis Primers. 6 (1): 61. doi:10.1038/s41572-020-0189-6. PMID 32703953 Check |pmid= value (help).
  3. 3.0 3.1 3.2 3.3 Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, Yang S, Hao Q, Wu Y, Song D, Zhang D, Lyu J, Dai Z (October 2019). "Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study". J Hematol Oncol. 12 (1): 107. doi:10.1186/s13045-019-0799-1. PMC 6805485 Check |pmc= value (help). PMID 31640759.
  4. Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC (August 2012). "Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis". Ann Oncol. 23 (8): 2128–2137. doi:10.1093/annonc/mdr578. PMID 22241896.
  5. Horesh N, Horowitz NA (October 2014). "Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy". Rambam Maimonides Med J. 5 (4): e0038. doi:10.5041/RMMJ.10172. PMC 4222427. PMID 25386354.
  6. "National Caner Institute Childhood Hodgkin Lymphoma Treatment".


Template:WikiDoc Sources